With a US filing for efgartigimod imminent, Belgian biotech argenx N.V. has presented more positive data on the potential first-in-class product which has been touted as a future standard of care for the rare autoimmune disease myasthenia gravis.
Additional data from the previously reported Phase III ADAPT trial which enrolled patients who were either acetylcholine receptor-antibody (AChR-A) positive...